DRNA - Dicerna Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.12
-1.19 (-6.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.31
Open17.99
Bid13.50 x 1200
Ask18.99 x 900
Day's Range16.60 - 18.67
52 Week Range10.70 - 27.68
Volume646,396
Avg. Volume714,750
Market Cap1.263B
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateMay 06, 2020 - May 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.00
  • Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic
    Business Wire

    Dicerna Addresses Business Continuity in Response to COVID-19 Pandemic

    Dicerna provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical development milestones.

  • Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals
    Investor's Business Daily

    Stocks Flashing Renewed Technical Strength: Dicerna Pharmaceuticals

    On Monday, Dicerna Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 69 to 92. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.

  • The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
    Benzinga

    The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) * Imara Inc (NASDAQ: IMRA)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) * 89bio Inc (NASDAQ: ETNB) * AC Immune SA (NASDAQ: ACIU) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adamis Pharmaceuticals Corp (NASDAQ: ADM) * Adial Pharmaceuticals Inc (NASDAQ: ADIL) * ADMA Biologics Inc (NASDAQ: ADMA) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Agenus Inc (NASDAQ: AGEN) * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Aikido Pharma Inc (NASDAQ: AIKI) * Akorn, Inc. (NASDAQ: AKRX) * Alkermes Plc (NASDAQ: ALKS) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * AngioDynamics, Inc. (NASDAQ: ANGO) * Anika Therapeutics Inc (NASDAQ: ANIK) * Anixa Biosciences Inc (NASDAQ: ANIX) * Antares Pharma Inc (NASDAQ: ATRS) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Aptinyx Inc (NASDAQ: APTX) * Arca Biopharma Inc (NASDAQ: ABIO) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Athenex Inc (NASDAQ: ATNX) * Avanos Medical Inc (NYSE: AVNS) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) * BIO-TECHNE Corp (NASDAQ: TECH) * BioCardia Inc (NASDAQ: BCDA) * BioDelivery Sciences International, Inc. (NASDAQ: BDSI) * BIOFRONTERA AG/ADR (NASDAQ: BFRA) * BIOLASE Inc (NASDAQ: BIOL) * BIOLINERX LTD/S ADR (NASDAQ: BLRX) * BioNano Genomics Inc (NASDAQ: BNGO) * BioSig Technologies Inc (NASDAQ: BSGM) * BioSpecifics Technologies Corp. (NASDAQ: BSTC) * BioTelemetry Inc (NASDAQ: BEAT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Boston Scientific Corporation (NYSE: BSX) * BridgeBio Pharma Inc (NASDAQ: BBIO) * Cabaletta Bio Inc (NASDAQ: CABA) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * CareDx Inc (NASDAQ: CDNA) * Catabasis Pharmaceuticals Inc (NASDAQ: CATB) * Catalent Inc (NYSE: CTLT) * Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cellectis SA (NASDAQ: CLLS) * CELYAD SA/ADR (NASDAQ: CYAD) * Chiasma Inc (NASDAQ: CHMA) * Chimerix Inc (NASDAQ: CMRX) * Coherus Biosciences Inc (NASDAQ: CHRS) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Dyadic International, Inc. (NASDAQ: DYAI) * Edesa Biotech Inc (NASDAQ: EDSA) * Elanco Animal Health Inc (NYSE: ELAN) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Enzo Biochem, Inc. (NYSE: ENZ) * Erytech Pharma SA (NASDAQ: ERYP) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evogene Ltd (NASDAQ: EVGN) * EXACT Sciences Corporation (NASDAQ: EXAS) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Flexion Therapeutics Inc (NASDAQ: FLXN) * Galera Therapeutics Inc (NASDAQ: GRTX) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) * Genocea Biosciences Inc (NASDAQ: GNCA) * Glaukos Corp (NYSE: GKOS) * Global Cord Blood Corp (NYSE: CO) * Global Blood Therapeutics Inc (NASDAQ: GBT) * GlycoMimetics Inc (NASDAQ: GLYC) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * Haemonetics Corporation (NYSE: HAE) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Harvard Bioscience, Inc. (NASDAQ: HBIO) * Helius Medical Technologies Inc (NASDAQ: HSDT) * Hepion Pharmaceuticals Inc (NASDAQ: HEPA) * Hologic, Inc. (NASDAQ: HOLX) * Illumina, Inc. (NASDAQ: ILMN) * Immunovant Inc (NASDAQ: IMVT) * Incyte Corporation (NASDAQ: INCY) * Innovate Biopharmaceuticals Inc (NASDAQ: INNT) * Innoviva Inc (NASDAQ: INVA) * Insmed Incorporated (NASDAQ: INSM) * Inspire Medical Systems Inc (NYSE: INSP) * Intec Pharma Ltd (NASDAQ: NTEC) * Integra Lifesciences Holdings Corp (NASDAQ: IART * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Iterum Therapeutics PLC (NASDAQ: ITRM) * Jaguar Health Inc (NASDAQ: JAGX) * Kalvista Pharmaceuticals Inc (NASDAQ: KALV) * KemPharm Inc (NASDAQ: KMPH) * Kezar Life Sciences Inc (NASDAQ: KZR) * Kindred Biosciences Inc (NASDAQ: KIN) * Kura Oncology Inc (NASDAQ: KURA) * Laboratory Corp. of America Holdings (NYSE: LH) * Lantheus Holdings Inc (NASDAQ: LNTH) * Liminal BioSciences Inc (NASDAQ: LMNL) * Lipocine Inc (NASDAQ: LPCN) * MacroGenics Inc (NASDAQ: MGNX) * Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) * Mallinckrodt PLC (NYSE: MNK) * Medigus Ltd. (NASDAQ: MDGS) * Medtronic PLC (NYSE: MDT) * MEI Pharma Inc (NASDAQ: MEIP) * MeiraGTx Holdings PLC (NASDAQ: MGTX) * Menlo Therapeutics Inc (NASDAQ: MNLO) * MEREO BIOPHARMA/ADR (NASDAQ: MREO) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Merus NV (NASDAQ: MRUS) * Midatech Pharma PLC-ADR (NASDAQ: MTP) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Morphosys Ag (NASDAQ: MOR) * MYOS Corporation common stock (NASDAQ: MYOS) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Natera Inc (NASDAQ: NTRA) * Natus Medical Inc (NASDAQ: NTUS) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO) * Neuronetics Inc (NASDAQ: STIM) * NewLink Genetics Corp (NASDAQ: NLNK) * Novus Therapeutics Inc (NASDAQ: NVUS) * NuVasive, Inc. (NASDAQ: NUVA) * Obalon Therapeutics Inc (NASDAQ: OBLN) * OptiNose Inc (NASDAQ: OPTN) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organovo Holdings Inc (NASDAQ: ONVO) * Orthofix Medical Inc (NASDAQ: OFIX) * Otonomy Inc (NASDAQ: OTIC) * Oxford Immunotec Global PLC (NASDAQ: OXFD) * Outlook Therapeutics Inc (NASDAQ: OTLK) * Pacific Biosciences of California (NASDAQ: PACB) * Pacira Biosciences Inc (NASDAQ: PCRX) * Passage Bio Inc (NASDAQ: PASG) * PDS Biotechnology Corp (NASDAQ: PDSB) * PLx Pharma Inc (NASDAQ: PLXP) * Precipio Inc (NASDAQ: PRPO) * Predictive Oncology Inc (NASDAQ: POAI) * Psychemedics Corp. (NASDAQ: PMD) * Quest Diagnostics Inc (NYSE: DGX) * Rapt Therapeutics Inc (NASDAQ: RAPT) * REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) * Regenxbio Inc (NASDAQ: RGNX) * resTORbio, Inc. (NASDAQ: TORC) * Retrophin Inc (NASDAQ: RTRX) * Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Salarius Pharmaceuticals Inc NASDAQ: SLRX * SCYNEXIS Inc (NASDAQ: SCYX) * Seneca Biopharma Inc (NASDAQ: SNCA) * Shockwave Medical Inc (NASDAQ: SWAV) * SI-Bone Inc (NASDAQ: SIBN) * Sierra Oncology Inc (NASDAQ: SRRA) * Silk Road Medical Inc (NASDAQ: SILK) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * Supernus Pharmaceuticals Inc (NASDAQ: SUPN) * SurModics, Inc. (NASDAQ: SRDX) * Takeda Pharmaceutical Co Ltd (NYSE: TAK) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TELA Bio Inc (NASDAQ: TELA) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Therapix Biosciences Ltd - ADR (NASDAQ: TRPX) * Theratechnologies Inc (NASDAQ: THTX) * Titan Medical Inc. (NASDAQ: TMDI) * Trevena Inc (NASDAQ: TRVN) * Trevi Therapeutics Inc (NASDAQ: TRVI) * Tricida Inc (NASDAQ: TCDA) * Trinity Biotech plc (NASDAQ: TRIB) * TrovaGene Inc (NASDAQ: TROV) * Twist Bioscience Corp (NASDAQ: TWST) * Urogen Pharma Ltd (NASDAQ: URGN) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Vascular Biogenics Ltd (NASDAQ: VBLT) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * VERONA PHARMA P/S ADR (NASDAQ: VRNA) * Viveve Medical Inc (NASDAQ: VIVE) * VIVUS, Inc. (NASDAQ: VVUS) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Xenetic Biosciences Inc (NASDAQ: XBIO) * Xenon Pharmaceuticals Inc (NASDAQ: XENE) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zimmer Biomet Holdings Inc (NYSE: ZBH) * Zoetis Inc (NYSE: ZTS) * Zogenix, Inc. (NASDAQ: ZGNX)See Also: 8 Biotechs With Coronavirus Vaccines In DevelopmentStocks In Focus Moleculin To Test Candidates For Coronavirus Canada's WPD Pharma said its licensing partner Moleculin Biotech Inc (NASDAQ: MBRX) has entered into an agreement with a leading government funded research facility in the U.S. to conduct research on its patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.In pre-market trading Thursday, Moleculin stock was rallying 134.49% to $1.10.Roche's Genentech To Evaluate Drug For COVID-19 Pneumonia Roche Holdings AG Basel ADR (OTC: RHHBY)'s Genentech unit said it is working with the BARDA to evaluate the safety and efficacy of Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.The company said the global study is expected to begin enrolling as soon as possible in early April with 330 patients.Novartis's Zolgensma Gets Japanese Regulatory Approval Novartis AG (NYSE: NVS) said the Japanese Ministry of Health, Labor and Welfare approved its gene therapy Zolgensma for treating spinal muscular atrophy in patients aged under two.Separately, the company said it is voluntarily recalling 100mg sandimmune and neural prescription drug blister packages due to the failure to meet child-resistant packaging requirement. If it is consumed by children, it exposes them to toxicity risk, the company said.Separately, the company announced publication in the New England Journal of Medicine results of three pivotal Phase III clinical trials for inclisiran, a siRNA investigational agent for hyperlipidemia in adults, which showed achievement of primary endpoints and safety.J&J Submits NDA For Multiple Sclerosis Drug Johnson & Johnson (NYSE: JNJ)'s Janssen unit announced the submission of an NDA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Bio-Rad's Real-Time qPCR Products Used by Labs For COVID-10 Screening Bio-Rad Laboratories, Inc. (NYSE: BIO) said its Real-Time qPCR products are being used by testing laboratories globally to screen for COVID-19.Dyadic's Platform to be Used By Israeli Research Institution to Develop COVID-19 Treatment Participating in the 32nd Annual ROTH Conference, which was held virtually, Dyadic said the Israeli Institute For Biologic Research will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both a rVaccine candidate and monoclonal antibodies for COVID-19 treatmentIn pre-market trading, the stock was adding 25.19% to $3.23.Qiagen's COVID-19 Test Gets CE Mark In Europe Qiagen NV (NYSE: QGEN) said it has obtained CE marking for its newly-developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic to detect SARS-CoV-2.Pfizer's Eczema Drug Aces Latestage Study Pfizer Inc. (NYSE: PFE) said the Phase 3 JADE COMPARE study that evaluated the safety and efficacy of abrocitinib, an investigational oral once-daily Janus kinase 1 inhibitor, in adults with moderate to severe atopic dermatitis who were also on background topical therapy, met its co-primary efficacy endpoints.View more earnings on IBB"These data, along with other results from other pivotal trials, MONO-1 and MONO-2, will support filings with regulatory bodies, starting with the US Food and Drug Administration (FDA) planned for later this year," the company said.Dicerna's Genetic Disorder Drug Gets Orphan Drug Designation Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) said the FDA granted orphan drug designation to its DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency - a genetic disorder that can cause lung and liver disease.In pre-market trading, the stock was adding 4.09% to $14.Earnings Capricor Therapeutics Inc's (NASDAQ: CAPR) fourth-quarter net loss narrowed from $1.05 per share to 34 cents per share, in line with the consensus. As of Dec. 31, 2019, cash, cash equivalents and marketable securities totaled about $9.9 million, compared to approximately $7.3 million on Dec. 31, 2018.In pre-market trading, the stock was slipping 5.36% to $1.18.Acer Therapeutics Inc (NASDAQ: ACER) said its fourth-quarter loss per share narrowed from 85 cents to 51 cents, while analyst estimated a narrower loss of 48 cents per share. Cash and cash equivalents were $12.1 million as of Dec. 31, 2019, compared to $41.7 million as of Dec. 31, 2018. The company said it believes its cash position will suffice to fund operations till the end of 2020, excluding support for Edsivo development and precommercial activities, and the planned osanetant clinical trial.Separately, the company said the Office of New Drugs of the FDA has denied its appeal of the Complete Response Letter for EDSIVO NDA.In pre-market trading, the stock was slipping 5.94% to $1.90.On The Radar Earnings Vascular Biogenics Ltd (before the market open) Zai Lab Ltd (NASDAQ: ZLAB) (before the market open) Hookipa Pharma Inc (NASDAQ: HOOK) (before the market open) BIOLASE Inc (NASDAQ: BIOL) (before the market open) Auris Medical Holding Ltd (NASDAQ: EARS) (after the close) Curis, Inc. (NASDAQ: CRIS) (after the close) Viveve Medical Inc (NASDAQ: VIVE) (after the close)See more from Benzinga * 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency
    Business Wire

    Dicerna Receives Orphan Drug Designation From U.S. Food and Drug Administration for DCR-A1AT for Treatment of Alpha-1 Antitrypsin Deficiency

    Dicerna announced that the FDA has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of alpha-1 antitrypsin (A1AT) deficiency.

  • Thomson Reuters StreetEvents

    Edited Transcript of DRNA earnings conference call or presentation 27-Feb-20 9:30pm GMT

    Q4 2019 Dicerna Pharmaceuticals Inc Earnings Call

  • Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Business Wire

    Dicerna™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 13 employees.

  • Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
    Simply Wall St.

    Earnings Beat: Dicerna Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

    Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares fell 5.3% to US$19.71 in the week since its latest full-year...

  • Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates
    Zacks

    Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates

    Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -625.00% and -73.18%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Investopedia

    3 Charts Suggest Micro-Cap Stocks Are Headed Higher

    Bullish chat patterns on small- and micro-cap stocks across the U.S. suggest that we could be in the early stages of a long-term uptrend.

  • Barrons.com

    Pharma and Biotech Aren’t Worried About Democratic Candidates’ Attacks Against Drugmakers

    Presidential candidates have the drug industry in their sights, but executives and investors say they are ready.

  • Dow Jones Futures Signal Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support
    Investor's Business Daily

    Dow Jones Futures Signal Gains To Start 2020: Tesla Deliveries Loom; Google, Disney Test Key Support

    Futures: Tesla deliveries loom but won't settle the Tesla stock debate. Google-parent Alphabet, Disney, Insulet, Five9 and Dicerna Pharmaceuticals are testing their 10-week lines.

  • We've made it to 2020. These are the top business issues to look for in the new year
    American City Business Journals

    We've made it to 2020. These are the top business issues to look for in the new year

    It's 2020 — do you have the vision it takes to grow your business in the new year? You have questions. We have answers. Where will cash-rich venture capital firms invest? Will New England, a higher education mecca, see additional closures and mergers of colleges and universities? What about potential treatments for cancer, rare diseases, and diabetes? Looking into the year ahead, Business Journal staffers asked the questions, and ferreted out some answers, and their potential impact on local business.

  • Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
    Zacks

    Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU

    The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.

  • Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails
    Investor's Business Daily

    Biotech Succeeds With Gene-Silencing Drug — But Its Stock Rally Fails

    Shares of Alnylam Pharmaceuticals tried to rally Tuesday after the biotech company's RNAi technology succeeded in a kidney disease. But Alnylam has some rivals waiting in the winds.

  • Atlas, MPM, Partners funnel $49M into a new gene-silencing startup
    American City Business Journals

    Atlas, MPM, Partners funnel $49M into a new gene-silencing startup

    Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.

  • The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders
    Simply Wall St.

    The Dicerna Pharmaceuticals (NASDAQ:DRNA) Share Price Has Soared 805%, Delighting Many Shareholders

    For us, stock picking is in large part the hunt for the truly magnificent stocks. Not every pick can be a winner, but...

  • Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Dicerna Pharmaceuticals Inc (DRNA)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%
    Zacks

    Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%

    Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

  • Thomson Reuters StreetEvents

    Edited Transcript of DRNA earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q3 2019 Dicerna Pharmaceuticals Inc Earnings Call

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Drug giant Roche acquires Lexington biotech for $390M
    American City Business Journals

    Drug giant Roche acquires Lexington biotech for $390M

    Drug giant Roche is buying another Boston area biotech startup, this time paying $390 million upfront for the company’s treatments for tissue scarring.

  • Benzinga

    The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...